Public Sector Pension Investment Board Has $1.73 Million Holdings in Edwards Lifesciences Co. (NYSE:EW)

Public Sector Pension Investment Board increased its position in Edwards Lifesciences Co. (NYSE:EW) by 12.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 26,167 shares of the medical research company’s stock after acquiring an additional 2,900 shares during the quarter. Public Sector Pension Investment Board’s holdings in Edwards Lifesciences were worth $1,727,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of EW. First Community Trust NA bought a new position in shares of Edwards Lifesciences in the second quarter worth about $29,000. Prospera Private Wealth LLC acquired a new position in shares of Edwards Lifesciences during the third quarter worth approximately $32,000. Avior Wealth Management LLC boosted its position in shares of Edwards Lifesciences by 138.7% in the third quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock valued at $35,000 after acquiring an additional 308 shares during the period. Webster Bank N. A. bought a new stake in shares of Edwards Lifesciences in the second quarter valued at approximately $39,000. Finally, Peoples Bank KS acquired a new stake in shares of Edwards Lifesciences in the third quarter worth $40,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Edwards Lifesciences Stock Down 2.4 %

Shares of Edwards Lifesciences stock opened at $72.43 on Friday. The business has a fifty day simple moving average of $68.55 and a 200 day simple moving average of $74.76. The stock has a market cap of $42.72 billion, a PE ratio of 10.45, a price-to-earnings-growth ratio of 3.95 and a beta of 1.12. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Co. has a 12 month low of $58.93 and a 12 month high of $96.12.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Thursday, October 24th. The medical research company reported $0.67 EPS for the quarter, meeting analysts’ consensus estimates of $0.67. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. The company had revenue of $1.35 billion during the quarter, compared to analysts’ expectations of $1.57 billion. During the same period in the prior year, the business posted $0.59 EPS. Edwards Lifesciences’s revenue was up 8.9% on a year-over-year basis. Research analysts predict that Edwards Lifesciences Co. will post 2.57 EPS for the current year.

Analyst Ratings Changes

EW has been the topic of several research analyst reports. JPMorgan Chase & Co. raised their price target on shares of Edwards Lifesciences from $72.00 to $78.00 and gave the stock a “neutral” rating in a research report on Friday, October 25th. Jefferies Financial Group lowered Edwards Lifesciences from a “buy” rating to a “hold” rating and decreased their price objective for the stock from $85.00 to $70.00 in a report on Wednesday, September 18th. Stifel Nicolaus boosted their price objective on Edwards Lifesciences from $70.00 to $75.00 and gave the company a “hold” rating in a research report on Thursday. Morgan Stanley reiterated an “equal weight” rating and set a $70.00 price target on shares of Edwards Lifesciences in a research note on Friday, October 11th. Finally, Canaccord Genuity Group increased their price objective on shares of Edwards Lifesciences from $63.00 to $68.00 and gave the company a “hold” rating in a research note on Thursday. Seventeen investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company. Based on data from MarketBeat, Edwards Lifesciences currently has an average rating of “Hold” and an average price target of $78.35.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,000 shares of Edwards Lifesciences stock in a transaction that occurred on Wednesday, September 11th. The shares were sold at an average price of $66.77, for a total value of $333,850.00. Following the transaction, the vice president now owns 46,936 shares of the company’s stock, valued at approximately $3,133,916.72. The trade was a 9.63 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Larry L. Wood sold 25,000 shares of the stock in a transaction on Tuesday, November 5th. The stock was sold at an average price of $65.91, for a total transaction of $1,647,750.00. Following the sale, the insider now directly owns 198,526 shares of the company’s stock, valued at $13,084,848.66. This represents a 11.18 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 40,000 shares of company stock valued at $2,657,000 over the last three months. 1.29% of the stock is currently owned by corporate insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.